Poster: In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Elena Iemma | Mar 14, 2023

Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides

by Elena Iemma | Mar 14, 2023

Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides  

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

by Annie De Groot | Sep 9, 2019

EpiVax_PANDA_Taspoglutide_April_19_Final

Predicting Immunogenicity of Peptide Drugs and Their Impurities Using in Silico Tools: Taspoglutide Case Study

by Annie De Groot | May 15, 2019

EpiVax_TaspoglutidePoster_14May19

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

by Annie De Groot | Oct 30, 2018

EpiVax_EuroTIDES_PANDA_02Nov18 To learn more about EpiVax’s PANDA Program, read our latest entries. PANDA screening Interview with Brian Roberts: Protein Therapeutics Manager PANDA Press Release